





Be **Sure** it's the right choice for her

New study confirms¹ using BD SurePath™ identifies more precursor lesions leading to fewer missed cases of cervical cancer

A comprehensive, independent study representing nearly 6 million samples from over 13 years of data taken from a national screening program concludes that using the BD SurePath™ Liquid-based Pap test results in a:



Using BD SurePath
When compared to
conventional cytology
Statistically significant




Using ThinPrep
When compared to
conventional cytology
Not statistically significant



New study confirms¹ BD SurePath™ performs better than other cytology methods

BD SurePath is associated with lower cervical cancer rates.²



Using ThinPrep® 8.5, fewer cervical cancers prevented**

Conventional baseline invasive cervical cancers at 72 months

Using BD SurePath 11.9, more cervical cancers prevented**

** Compared to conventional cytology. per 100,000 screened women

Author's conclusions

Using BD SurePath rather than conventional cytology or ThinPrep as the primary test method was associated with lower cervical cancer rates diagnosed after a normal screening sample.

This strongly suggests that the sensitivity of BD SurePath to detect progressive CIN lesions is higher.

About the Publication

This independent analysis was conducted by Erasmus University Medical Center for the Department of Public Health, Rotterdam, Netherlands.

The analysis was based upon the cancer registry available in the Netherlands and the use of the PALGA data base, which is a national registry of all cytology and histology reports related to the detection of cancer, including cervical cancer. It evaluates the clinical significance of the increased detection of Cervical Intraepithelial Neoplasia (CIN) grades 2 and above on the risk of developing cancer between screening periods.

1. Previous Studies: Fremont-Smith M, et al. Comparison of the SP liquid-based Pap smear with the conventional Pap smear in a multisite direct-to-vial study. Cancer. 2004; Kirsten Rozemeijer et al. Comparing SurePath, ThinPrep, and conventional cytology as primary test method: SurePath is associated with increased CIN II+ detection rates Cancer Causes Control DOI 10.1007/s10552-015-0678-1

2. Rozemeijer Kirsten, Naber Steffie K, Penning Corine, Overbeek Lucy I H, Looman Caspar W N, de Kok Inge M C M et al. Cervical cancer incidence after normal cytological sample in routine screening using SurePath, ThinPrep, and conventional cytology: population based study. BMJ 2017; 356:j504

BD, Sparks, MD 21152-0999 USA
800.638.8663

bd.com

ThinPrep is a registered trademark of Hologic, Inc.
© 2017 BD. BD, the BD Logo and SurePath are trademarks of Becton, Dickinson and Company.
0-223889 August 2017 Printed in the U.S.A.

